Market Trends - The current market situation is characterized by maximum uncertainty, with potential opportunities for high-quality blue-chip companies affected by recent downturns [2] - Historical data shows that selling during periods of market distress, such as the Silicon Valley Bank collapse or COVID-19, resulted in missing significant recoveries of 78% and 198% respectively [3] - The timing of geopolitical events, such as the Iran war, is crucial; a shorter conflict may allow the economy to continue growing, while a prolonged one could lead to stagnation [2][3] Healthcare Stocks - A list of 11 high growth healthcare stocks has been compiled based on a high 5-year revenue growth rate (over 25%) and popularity among elite hedge funds as of Q3 2025 [6] - The methodology for selecting these stocks involved using stock screeners and analyzing hedge fund sentiment [6][7] Zai Lab Limited (NASDAQ:ZLAB) - Zai Lab Limited reported a 17% year-over-year revenue growth to $127.6 million for fiscal Q4 2025 and a 15% growth to $460.2 million for the full year [10] - The company is on track for its first global oncology launch with Zocilurtatug pelitecan, expected to complete three registration-enabling studies by the end of 2026 [10][11] - Zai Lab is advancing a differentiated global pipeline, including several key therapies and regional programs, with commercial launch preparations for KarXT in China underway [11][12] ImmunityBio Inc. (NASDAQ:IBRX) - ImmunityBio received a warning letter from the FDA regarding misleading promotional communications for its product Anktiva, which has led to a directive to cease certain advertisements [13][14] - The company is a clinical-stage immunotherapy firm focused on developing next-generation therapies for cancer and infectious diseases [15]